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Abstract
 
We investigated the in vivo role of CD69 by analyzing the susceptibility of CD69
 

 
/
 

 
 mice
 
to tumors. CD69
 

 
/
 

 
 mice challenged with MHC class I
 

 
 tumors (RMA-S and RM-1)
showed greatly reduced tumor growth and prolonged survival compared with wild-type
(WT) mice. The enhanced anti–tumor response was NK cell and T lymphocyte–mediated,
and was due, at least in part, to an increase in local lymphocytes. Resistance of CD69
 

 
/
 

 
mice to MHC class I
 

 
 tumor growth was also associated with increased production of the
chemokine MCP-1, diminished TGF-
 

 
 production, and decreased lymphocyte apoptosis.
Moreover, the in vivo blockade of TGF-
 

 
 in WT mice resulted in enhanced anti–tumor re-
sponse. In addition, CD69 engagement induced NK and T cell production of TGF-
 

 
, di-
rectly linking CD69 signaling to TGF-
 

 
 regulation. Furthermore, anti-CD69 antibody
treatment in WT mice induced a specific down-regulation in CD69 expression that resulted
in augmented anti–tumor response. These data unmask a novel role for CD69 as a negative
regulator of anti–tumor responses and show the possibility of a novel approach for the ther-
apy of tumors.
Key words: cytokines • homeostasis • apoptosis
 
Introduction
 
AIM/CD69 is the earliest activation cell surface receptor
on leukocytes. CD69 is a C-type lectin, disulfide-linked
homodimer (24 kD), type II protein (1). The genetic and
biochemical characteristics of mouse CD69 are very similar
to its human homologue. CD69 is constitutively expressed
by platelets, mature thymocytes, bone marrow myeloid,
and lymphoid precursors. CD69 is not detected in periph-
eral blood lymphocytes, but it is expressed by small subsets
of T and B cells in peripheral lymphoid tissues (2, 3). Nev-
ertheless, CD69 does not appear to be required for the de-
velopment of any bone marrow cell lineage because nearly
normal hematopoietic cell development and T cell matura-
tion occur in CD69
 

 
/
 

 
 mice. Only minor alterations are
observed in B cell development in these mice, with
the B220
 
hi
 
IgM
 
neg
 
 bone marrow pre–B cell compartment
slightly augmented (4).
CD69 expression is induced by cytokine stimulation on
leukocytes (5, 6). Accordingly, CD69
 

 
 T lymphocytes are
detected in cell infiltrates of various chronic inflammatory
diseases (7). Moreover, CD69 is expressed by activated T,
B, and NK cells and monocytes in LPS-treated mice (8).
On the other hand, the intracellular signals induced
through CD69 result in cytokine and cytokine receptor
 
synthesis in T cells (3, 9–12). CD69 expression is induced on
 
NK cells by IL-2 (5), IFN-
 

 
 (13), cross-linking of Fc
 

 
RIII,
and activators of PKC (14). Furthermore, stimulation of
activated NK cells with anti-CD69 antibodies stimulates
cytolytic activity (15).
Chemokines and cytokines control leukocyte attraction
and activation, whereby regulating immune homeostasis.
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Role of CD69 in Tumor Immunity
 
Monocyte chemotactic protein-1 (MCP-1)
 
*
 
 chemokine is
produced early after exposure to immune stimuli (16), and
has been implicated in enhancing lymphocyte migration
and cytotoxicity (17). Furthermore, animals that lack
MCP-1 show diminished T cell responses (18). TGF-
 

 
prevents and/or suppresses inflammatory responses, regu-
lating production of proinflammatory cytokines (for review
see reference 19). Several clinical and experimental obser-
vations suggest that CD69 expression is regulated, at least
in part, by these cytokines. In this regard, it has been de-
scribed previously that TGF-
 

 
 down-regulates the expres-
sion of CD69 in factor VIII–treated patients (19a). In
addition, tumor patients treated with proinflammatory cy-
tokines show increased levels of immunosuppressive cyto-
kines (e.g., IL-10 and TGF-
 

 
) and decreased tumor infil-
tration by CD69
 

 
 lymphocytes (20).
The immune response against tumors involves the com-
bined action of humoral and cellular mechanisms, in which
macrophages, cytotoxic T, and NK lymphocytes play a
central role. Tumor models have provided useful tools to
dissect complex anti–tumor immune responses (21, 22).
Here, we analyzed the influence of CD69 deficiency on
the anti–tumor response in CD69
 

 
/
 

 
 mice. CD69
 

 
/
 

 
mice showed an enhanced NK cell–dependent response
that leads to a higher protection and rejection of MHC
class I
 

 
 tumor cells compared with wild-type (WT) mice.
This potent anti–tumor response was dependent on the tu-
mor–host microenvironment, correlating with a dimin-
ished TGF-
 

 
 production and an increase in inflammatory
cytokines and MCP-1, and was associated with increased
recruitment of lymphoid effector cells and diminished
apoptosis. In addition, the in vivo blockade of TGF-
 

 
 in
WT mice increased anti–tumor response. Moreover, we
found that cross-linking of CD69 induced TGF-
 

 
 produc-
tion, directly linking CD69 signaling to TGF-
 

 
 regulation.
Furthermore, down-modulation of CD69 expression in-
duced in WT mice through anti-CD69 antibody treatment
produced increased anti–tumor response. These findings
reveal a novel role for CD69 as a negative regulator of im-
mune homeostasis through TGF-
 

 
 modulation.
 
Materials and Methods
 
Mice.
 
Mice were bred at the Centro Nacional de Biotec-
nología under specific pathogen-free conditions and at the Uni-
versity of Barcelona in a conventional facility. All experiments
were performed using mice on a C57BL/6 genetic background
except in in vivo homing assays and in in vivo tumor challenges
in RAG2
 

 
/
 

 
, which were performed in BALB/c mice.
CD69
 

 
/
 

 
 mice were backcrossed on C57BL/6 or BALB/c
background at least nine times. C57BL/6, BALB/c WT, and
gene-targeted CD69
 

 
/
 

 
 mice (4) were 6–12 wk old, and litter-
mate or age-matched litters, whose parents were littermates, were
used as controls. C57BL/6, BALB/c, and RAG2
 

 
/
 

 
 mice were
purchased from Jackson ImmunoResearch Laboratories. For the
generation of RAG2
 

 
/
 

 
 
 

 
 CD69
 

 
/
 

 
 mice, the status of the
 
RAG2 locus was followed by assaying blood for CD3
 

 
 cells by
FACS
 
®
 
. Genotyping of the CD69 locus was performed by poly-
merase chain reaction as described previously (4). All procedures
involving animals and their care were approved by the Ethics
Committee of the University of Barcelona and were conducted
according to institutional guidelines that are in compliance with
national (Generalitat de Catalunya decree 214/1997, DOGC
2450) and international (Guide for the Care and Use of Labora-
tory Animals, National Institutes of Health, 85–23, 1985) laws
and policies.
 
Cell Culture.
 
The RM-1 prostate carcinoma (H-2
 
b
 
, a gift
from Dr. T. Thompson [Baylor College of Medicine, Houston,
TX]), YAC-1 (H-2
 
a
 
), RMA (H-2
 
b
 
) lymphoma cell lines, RMA-S
(H-2
 
b
 
) mutant lymphoma cells (derived from Rauscher virus–
induced murine cell line RBL-5 and defective for peptide loading
of MHC class I molecules), and 300.19 pre–B cells were cultured
in RPMI 1640 medium supplemented with 10% heat-inactivated
FCS, 2 mm 
 
l
 
-glutamine, 100 U/ml penicillin, and 100 
 

 
g/ml
streptomycin (GIBCO BRL) at 37
 
	
 
C, 5% CO
 
2
 
.
 
Cell Isolation.
 
Peritoneal macrophages were isolated by plastic
adhesion, and further subset purification was performed with
magnetic beads (Miltenyi Biotec) and specific biotin-conjugated
Ab (BD Biosciences), yielding 
 

 
98% cell purity.
 
Tumor Control In Vivo.
 
Tumor cells (RMA, RMA-S, or
RM-1) in 0.2 ml PBS were injected intraperitoneally or subcuta-
neously in untreated WT and CD69
 

 
/
 

 
 mice, and in antibody-
depleted mice, as indicated
 
.
 
 In experiments performed with NK
cell–depleted mice, animals were injected intraperitoneally with
100 
 

 
l rabbit anti–asialo-GM-1 (Wako Chemicals) 1 d before tu-
mor inoculation, and at days 
 

 
2 and 
 

 
4 after tumor challenge.
Mice were treated for lymphocyte T CD4
 

 
 depletion on day 
 

 
1
(before tumor challenge), and at days 
 

 
2 and 
 

 
4 after tumor in-
oculation with either GK1.5 anti-CD4 or isotype control mAbs
(100 
 

 
l/injection). Mice were observed by monitoring body
weight daily for tumor ascites development for 12 wk. Mice were
killed, for ethical reasons, when the body weight had increased
by 25%, corresponding to note obvious signs of irreversible tu-
mor growth, and when the animals became moribund.
 
RM-1 Lung Colonization.
 
10
 
4 
 
RM-1 cells suspended in 100 
 

 
l
PBS were injected into the tail vein of CD69
 

 
/
 

 
 and WT mice.
Mice were killed 14 d later, the lungs were removed and fixed in
4% paraformaldehyde solution, and individual surface lung me-
tastases were counted with the aid of a dissecting microscope.
 
Flow Cytometry.
 
Spleen and peritoneal exudate cells (10
 
6
 
)
were first preincubated with a blocking solution (PBS with 5%
heat-inactivated FCS, 15% heat-inactivated rabbit serum, 0.02%
sodium azide and 2.4G2 mAb) to avoid binding of Abs to Fc
 

 
 re-
ceptors. Cells were stained for 30 min on ice with FITC- or PE-
conjugated antibodies or with biotinylated antibodies followed by
streptavidin-FITC or -PE (Southern Biotechnology Associates,
Inc.) The following antibodies were used: anti-DX5 (DX5), -2B4
(2B4), CD2 (RM2–5), -CD3 (145–2C11), -B220/CD45 (RA3–
6B2), -CD4 (GK1.5), -CD5 (53–7.3), -CD8 (53–6.7), -CD11b
(M1/70), -Ly6G (RB6–8C5), IgM (G155–228), and -CD69
(H1.2F3; all from BD Biosciences) and IgD (Southern Biotech-
nology Associates, Inc.; 11–26). Finally, cells were washed and
analyzed on a FACSCalibur™ flow cytometer (Becton Dickin-
son), counting 10
 
4
 
 live cells and using CELLQuest™
 
 
 
software
(Becton Dickinson). The number of cells migrating to the perito-
neum was determined with a Multisizer II (Beckman Coulter).
 
IL-2–activated NK Cells.
 
Purified spleen NK cells were ob-
tained with the CELLection Biotin Binder Kit (Dynal) and biotin-
ylated anti-DX5 antibody, according to manufacturer’s instruc-
 
*
 
Abbreviations used in this paper:
 
 MCP-1, monocyte chemotactic protein-1;
PI, propidium iodide; RPA, RNase protection assay; WT, wild-type.
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tions. In brief, viable single cell suspensions were incubated (1 h
at 37
 
	
 
C) on polystyrene tissue culture dishes (Becton Dickinson).
Nonadherent spleen cells were incubated (15 min at 4
 
	
 
C) with
biotinylated anti-DX5 antibody, washed twice, and CELLection
biotin magnetic Dynabeads (10
 
7
 
 magnetic beads per 10
 
6
 
 cells)
were added to capture antibody-coated cells. Cell purity was al-
ways 
 


 
98% DX5
 

 
. NK cells were cultured in complete medium
with 20% inactivated FCS, alone, or with 1,000 UI/ml human
rIL-2 (72 h).
 
51
 
Cr Release Assays.
 
Direct NK cell cytotoxic activity was as-
sessed by a standard 
 
51
 
Cr release assay. In all experiments, 5 
 

 
 10
 
3
 
sodium [
 
51
 
Cr]chromate-labeled YAC-1 target cells were mixed
with effector cells at the ratios indicated (4 h at 37
 
	
 
C). Spontane-
ous 
 
51
 
Cr release was determined by incubating target cells with
medium alone; maximum release was determined by adding
TritonX100 at a final concentration of 2.5%. The percentage of
specific lysis was calculated as percentage specific lysis 
 

 
 ([sample
cpm 
 

 
 spontaneous cpm]/[maximal cpm  spontaneous cpm]) 
100. Spontaneous 51Cr release was always 10%, and all experi-
ments were performed in triplicate.
In Vivo Homing Assays. Lymphocytes were isolated from sin-
gle cell suspensions of lymph nodes, spleen, and other organs. For
isolation of CD4 T lymphocytes, cells were incubated with anti-
CD8 and anti–MAC-1 mAb, followed by two panning steps on
petri dishes coated with a rabbit anti–mouse/rat IgG (DakoCyto-
mation) at 4	C. The average purity of CD4 cells was 
95%, as
determined by flow cytometry analysis.
The migration of radioactively labeled lymphocytes was ana-
lyzed as described previously (38). In brief, cells were labeled
with 20 Ci/ml sodium [51Cr]chromate (1 h at 37	C). Dead cells
were removed by centrifugation on a density cushion (Nyco-
denz). 0.5–2  106 cells suspended in 0.3 ml PBS were injected
into the tail vein. Mice were killed 1 or 24 h later, and the distri-
bution of the radioactivity in different organs and the remaining
body was measured.
Cell Death Assays. Splenocytes (4  106 cells/ml) from chal-
lenge mice (3 d with 105 RM-1) were cultured in 24-well plates
(Costar), and cell death was assayed 24 h after the initiation of
culture. Cell cycle was monitored, cells were stained with pro-
pidium iodide (PI), and apoptosis was determined by flow cyto-
metric analysis on an XL cytometer (Beckman Coulter). Data are
expressed as mean  SE (n  9). Caspase-3 activity was assayed at
48 h after initiation of culture by incubation with the PhiPhiLux-
G1D2 substrate solution (OncoImmunin) according to the man-
ufacturer’s protocol. Flow cytometric analysis was performed
within 60 min of the end of the incubation period with an XL
cytometer. Peritoneal cells (106) from untreated mice were cul-
tured in 24-well plates, and cell death was assessed, at indicated
time points, by PI staining. PI-stained samples were considered
apoptotic cells.
RNase Protection Assay (RPA) and Quantitative Real-time RT-
PCR Analyses. Total RNA was extracted from unfractionated
peritoneal cells using Tri Reagent (Sigma-Aldrich) as recom-
mended. RPAs were performed on 1–20 g of total RNA using
the Riboquant MultiProbe RNase Protection Assay System (BD
Biosciences), following manufacturer’s instructions. Multiprobe
template sets mCK2b, mCK3b, and mCK5 were used. DNA
templates were used to synthesize the [32P]UTP (3,000 Ci/mmol
or 10 mCi/ml; Amersham Biosciences)-labeled probes in the
presence of a GACU pool using a T7 RNA polymerase. Hybrid-
ization with 1–20 g of each target RNA was performed over-
night, followed by digestion with RNase A and T1 according to
the standard protocol. Samples were treated with a proteinase
K–SDS mixture, extracted with chloropan, and precipitated in
the presence of ammonium acetate. Samples were run in an acryl-
amide-urea sequencing gel, next to the labeled probes, at 45 W
with 0.5 Tris-borate/EDTA buffer (TBE). The gel was ad-
sorbed to filter paper, dried under vacuum, and exposed on a film
(X-AR; Kodak) with an intensifying screen at 70	C. For RT-
PCR, 2 µg DNaseI-treated RNA was reverse transcribed with
MuLV RT (Roche Diagnostics, Ltd.). Real-time PCR was per-
formed in a rapid thermal cycler system (Lightcycler; Roche Di-
agnostics, Ltd.) with primers from different exons that generated
products of 200 bp in length. Results for each cytokine are
normalized to GAPDH expression and measured in parallel in
each sample.
Blockade of TGF-. In vivo blocking of active TGF- in tu-
mor challenge mice was performed by administration of 0.5 mg
mAb against TGF- (1D11.16.8; mouse IgG1 hybridoma, pur-
chased from American Type Culture Collection; reference 50),
or PBS on days 3, 1, and 1 relative to tumor inoculation
and every week after tumor inoculation.
mAb Production. A new panel of mouse CD69-specific mAb
was generated by fusion of NS-1 myeloma cells with spleen cells
from a CD69-deficient mouse immunized previously three times
with mouse 300-19 pre–B cells. Supernatant fluid from hybrid-
oma-containing wells was screened for reactivity with mCD69-
transfected Jurkat cells; 42 supernatants reacted with mouse
cDNA CD69-transfected Jurkat cells, but not untransfected cells.
These hybridomas were selected for characterization and were
subcloned twice. Antibody isotypes were determined with a
mouse mAb isotyping kit (Boehringer). Antibodies were used ei-
ther as undiluted culture supernatant or were purified from con-
centrated supernatants obtained in a CL 350 flask (Integra Bio-
sciences AG) with a protein G column (Amersham Biosciences).
Purified mAb were dialyzed extensively against PBS, and their
purity was assessed by SDS-PAGE. mAbs were stored at 20	C.
TGF- and MCP-1 Production and ELISA. For in vitro
TGF- production in NK cells, spleen DX5 cells of C57BL/6
mice were obtained. 2.5  105 NK cells were plated in U-bot-
tomed 96-well plates in 200 l of serum-free Stem Span (Stem-
Cell Technologies Inc.) medium. Purified anti-CD69, clone
CD69.2.2 (IgG1-), or control mouse IgG1 mAb were added at
10 g/ml. For cross-linking, F(ab)2 fragments of goat anti–
mouse IgG Fc-specific antibody (Jackson ImmunoResearch Lab-
oratories) were added at a final concentration of 20 g/ml. For in
vitro TGF- production in T lymphocytes, purified CD3 T
cells from single cell suspensions of lymph nodes and spleen of
C57BL/6 or BALB/c mice were obtained. For isolation of
CD3 T lymphocytes, cells were incubated with anti–MAC-1
mAb, followed by two panning steps on petri dishes coated with
rabbit anti–mouse/rat IgG (DakoCytomation) at 4	C. The aver-
age purity of CD3 cells was 
95%, as determined by flow cy-
tometry analysis. T lymphocytes were stimulated (2  106 cells/
ml) with 1 µg/ml of plate-bound anti-CD3 mAb. Cells were
added in 200 l of serum-free Stem Span medium in flat-bot-
tomed 96-well plates. Anti-CD69, clone CD69.2.2 (IgG1-), or
control mouse IgG1 mAb were added at 20 µg/ml. For cross-
linking, F(ab)2 fragments of goat anti–mouse IgG Fc-specific an-
tibody were added at a final concentration of 20 g/ml. Cultures
were incubated (37	C, 5% CO2), supernatants were collected af-
ter 24, 48, and 72 h, and secreted TGF- was assayed with a
TGF-1 Emax ImmunoAssay System (Promega) ELISA kit, ac-
cording to the manufacturer’s protocol. To measure MCP-1 pro-
duction, 1 ml of thioglycollate solution (3% wt/vol; Sigma-
Aldrich) was injected intraperitoneally into CD69/ and WT
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mice. Mice were killed 3 d later, and leukocyte infiltrate was re-
covered by peritoneal lavage using 5 ml of cold RPMI 1640 with
2% FCS. Peritoneal cells were added in 1 ml of complete me-
dium in flat-bottomed 24-well plates and stimulated overnight
with 1 µg/ml LPS at 2  106 cells/ml. Culture supernatants were
collected and MCP-1 was assayed with a mouse MCP-1 OptEIA
ELISA Set (BD Biosciences).
Analysis of Cell Viability. T cells were cultured as done for
the TGF- production assay; after 24- and 48-h culture, cell via-
bility was determined by trypan blue addition.
Statistical Analysis. Where indicated, Student’s t-test for non-
paired data and Mann-Whitney U test were used to calculate sta-
tistical significance for difference in a particular measurement be-
tween different groups. Statistical significance was set at P  0.05.
Results
Enhanced In Vivo Anti-tumor NK Cell Activity in CD69/
Mice. NK cells are reported to mediate the immune
response to MHC class I RMA-S tumor cells, whereas
CD8 CTLs mediate the response to the parental RMA
cells bearing MHC class I (22, 23). To evaluate the possible
role of CD69 in in vivo anti-tumor function, WT and
CD69/ mice were injected intraperitoneally with
RMA-S cells and tumor progression was analyzed (Fig. 1
A). In response to 104 RMA-S cells, all WT mice devel-
oped tumors by 5 wk after injection, with a detectable
weight increase at day 15, whereas only 20% of CD69/
mice developed detectable tumors even as late as 7 wk (Fig.
1 A). Animals that did not develop tumors were followed
for up to 3 mo without any sign of tumor progression.
Similar results were observed when mice were subcutane-
ously injected with 105 RMA-S cells (Fig. 1 B), indicating
that there are no appreciable differences due to the site of
tumor challenge. In contrast, only slight differences were
observed in the progression of H-2 RMA cell tumors be-
tween WT and CD69/ mice (Fig. 1 C and not de-
picted), thus suggesting that CD8 CTLs do not play a ma-
jor role in the enhanced anti–tumor response observed in
CD69/ mice.
Previous studies showed that NK cells control RMA-S
growth in vivo in WT mice (22). To further investigate the
involvement of NK cells in the control of RMA-S tumor
growth in CD69/ mice, animals were depleted of NK
cells before tumor induction by treatment with anti–asialo-
GM1 serum. Injection with either control diluent or anti–
asialo-GM1 was initiated on day 1 before tumor chal-
lenge and was continued on days 2 and 4 after tumor
inoculation. As predicted, tumor growth was observed in
all NK cell–depleted mice but in none of the control mice
(Fig. 1 D). Anti–asialo-GM1-treated CD69/ mice de-
veloped tumors within the first 10 d after tumor inocula-
tion, which was comparable to the earliest RMA-S tumor
Figure 1. Increased NK anti-tumor activity in CD69/ mice. Mice were injected intraperitoneally with 104 RMA-S (A) or RMA (C) tumor cells.
Mice were observed daily for tumor growth up to 12 wk by monitoring body weight and ascites development. Similar results were observed in mice in-
jected subcutaneously with 105 RMA-S (B). (A, n  9; B, n  6; C, n  9.) (D) NK or T lymphocytes were depleted from CD69/ mice before in-
traperitoneal inoculation with 104 RMA-S tumor cells. Mice were treated for NK cell depletion on day 1 (before tumor challenge), and at days 2 and
4 after tumor inoculation with either control diluent or anti–asialo-GM1 antiserum (100 l/injection). Mice were treated for lymphocyte T CD4 de-
pletion on day 1 (before tumor challenge), and at days 2 and 4 after tumor inoculation with either GK1.5 anti-CD4 or isotype control mAbs (100
l/injection). (D, n  7) Results shown are representative of two independent experiments. (E) Photographs are of lungs from CD69/ and WT
mice 2 wk after the challenge with 104 RM-1 cells intravenous inoculation (top). One representative mouse out of 10 per group is shown. The number
of lung metastases were counted (bottom) and each symbol represents one mouse. Open symbols, WT mice; closed symbols, CD69/ mice. Results
are representative of two independent experiments.
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development observed in perforin-deficient C57BL/6 mice
(22, 24). The depletion of CD4 or CD8 lymphocytes in
CD69/ mice increased tumor development but to a
lesser extent than NK cell depletion (Fig. 1 D and not de-
picted). These results indicate that although NK cells are
critically involved in RMA-S tumor rejection in CD69/
mice, T cells also play a role in this process. The increased
anti-tumor activity in CD69/ mice was not restricted
to RMA-S cells, because it was also observed after chal-
lenge with C57BL/6 syngeneic RM-1 class I prostate car-
cinoma cells. Study of lung metastases in CD69/ mice
compared with WT mice challenged intravenously with
104 RM-1 cells showed a greater number of pulmonary
metastases in WT mice, whereas CD69/ mice re-
mained almost free from metastases (Fig. 1 E).
Increased Anti–tumor Response in CD69/RAG2/-
deficient mice. To analyze the contribution of innate im-
munity to the enhanced anti–tumor response observed
in CD69/ mice, CD69/RAG2/ mice and
CD69/RAG2/ mice were injected intraperito-
neally with 106 RMA-S cells and tumor progression was
analyzed (Fig. 2). In response to injection of RMA-S cells,
tumor cell overgrowth was observed in all CD69/
RAG-deficient mice by 3 d, whereas tumor cell growth
was almost completely inhibited in CD69/ RAG2/
mice (Fig. 2). Therefore, increased control of RMA-S
overgrowth was observed in CD69/RAG2/ mice
3 d after tumor inoculation, and these results are in agree-
ment with the major relevant role of NK cells in MHC
class I negative tumor suppression in CD69/ mice.
CD69/ Mice Show Unaltered NK Cell Function. To
assess whether tumor rejection was associated with in-
creased NK cell function, the lytic activity of peritoneal
cells of RMA-S–primed CD69/ and WT mice was de-
termined based on their ability to lyse NK-susceptible
YAC-1 tumor cells in vitro. Freshly isolated unfractionated
peritoneal cells from RMA-S–inoculated (day 3) CD69/
mice were more efficient in killing YAC-1 than those
from WT mice (Fig. 3 A), thus showing a correlation be-
tween the in vivo NK immune response and in vitro
NK cytotoxicity in CD69/ mice. Increased tumor-
induced NK cytolytic activity in CD69/ mice was also
observed after challenge with RM-1 prostate carcinoma
cells (Fig. 3 B). However, when in vitro NK cell cytolytic
assays were performed with purified DX5 CD3 NK
splenocytes and YAC-1 targets, no differences between
CD69/ and WT mice were observed (Fig. 3 C).
Moreover, no differences were found when purified NK
cells were expanded by culture in IL-2 and assayed for cy-
tolytic activity (Fig. 3 D). Thus, CD69/ mice have
normal levels of NK activity in the spleen, indicating that
the cytolytic potential of CD69/ NK cells is unaltered
by the absence of CD69.
Increased Local NK Cells and T Lymphocyte Accumulation
in CD69/ Mice. To investigate the mechanism ac-
counting for the enhanced anti–tumor response that corre-
lates with the increased cytotoxic activity of unfractionated
peritoneal cells, the peritoneum of CD69/ animals was
analyzed. NK cells, T lymphocytes, and total peritoneal
Figure 2. Exacerbated anti–tumor response in CD69/RAG-defi-
cient mice. Mice were injected intraperitoneally with 106 RMA-S tumor
cells. Total unfractionated peritoneal cells from CD69/ and CD69/–
RAG2/ mice were examined 72 h after tumor inoculation. Forward
and scattered FACS® analysis. Marked gates correspond to RMA-S tumor
cells. One representative mouse out of 10 per group is shown. Results
shown are representative of two independent experiments (n  8).
Figure 3. Increased ex vivo NK cytotoxicity in
CD69/ mice. Mice received 104 RMA-S (A) or
RM-1 cells (B) intraperitoneally 72 h after inoculation,
total unfractionated peritoneal cells (A and B) from
CD69/ and WT mice were analyzed for cytotox-
icity against YAC target cells. Two animals were used
per experimental group (mean  SE). (C and D) Puri-
fied NK cells were used, untreated or treated with IL-2,
respectively. (D) Two animals were used per experi-
mental group (mean  SE). Open symbols, WT;
closed symbols, CD69/. The results are representa-
tive of three similar experiments.
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1098 Role of CD69 in Tumor Immunity
cells were quantified in mice that were unchallenged or
challenged with RM-1 or RMA-S cells. Peritoneal NK
cells were defined as staining positive with antibodies DX5
and 2B4 by two color flow cytometry. As shown in Fig. 4
and Table I, the total cellularity in unchallenged peritoneal
lavage was moderately increased in CD69/ mice com-
pared with WT mice. This was likely due to an increase in
the number and proportion of lymphocytes; specifically,
NK cells and CD3 T lymphocytes (twofold; Table I A).
Upon the RM-1 tumor challenge, the total number of cells
recruited to peritoneum in CD69/ mice was signifi-
cantly increased compared with WT mice (Fig. 4 and Ta-
ble I A). This reflects an increase in lymphocyte recruit-
ment; the number of NK cells and CD3 T lymphocytes
was almost threefold higher in CD69-deficient mice com-
pared with WT mice (Fig. 4 and Table I). In contrast, the
number of peritoneal CD5B220 B-1 and CD5B220
B-2 lymphocytes was similar in CD69/ and WT mice,
both under basal conditions and after tumor challenge with
RM-1 (unpublished data). We detected only slight in-
creases in monocytes and granulocytes in CD69/ peri-
toneum compared with WT mice (unpublished data).
These data reveal a correlation between the number of NK
cells and CD3 T lymphocytes in the peritoneum of
CD69/ mice and the anti–tumor response. Similar re-
sults were observed when mice were intraperitoneally chal-
lenged with RMA-S cells (unpublished data). Thus, CD69
does not appear to regulate NK cell cytolytic activity per
se, but instead regulates the number of NK cells and CD3
T lymphocytes recruited to the site of tumor challenge.
The spleen is a lymphoid organ strongly influenced by
peritoneal inflammation. Accordingly, at day 6 of tumor
challenge, CD69/ mouse spleens were much enlarged
compared with those of WT mice (unpublished data).
Spleen cell counts showed a similar trend (Table I), although
flow cytometric analyses revealed similar proportions of
Figure 4. Peritoneal cell accumulation in CD69/ mice in response
to MHC class I tumor cells. Mice were injected intraperitoneally with
PBS or with 105 RM-1 cells (n  7, mice/group). Cells collected from
the peritoneal lavage were analyzed by FACS® and a Multisizer cell
counter, and total leukocyte numbers (106) determined at the indi-
cated times.
Table I. Basal and RM-1 Challenged
A. Peritoneum
Total cellsa
Percent NK 
cellsb Total NKSc
Percent CD3
cellsd
Total CD3
cellse
106 104 104
Basal WT 3.29  0.08 0.96  0.07 3.15 8.36  1.04 27.5
KO 4.01  0.12 1.64  0.10 6.57 14.60  0.65 58.54
RM-1 (3 d) WT 6.24  0.90 2.50  0.21* 15.6 12.75  0.57 79.56
KO 11.39  1.28 3.51  0.31 39.97 18.42  0.89 209.8
B. Spleen
Basalf RM-1 (3 d)g RM-1 (6 d)h
Total cells (106) WT 63.78  5.12* 68.4  4.54 88.52  7.09
KO 96.71  10.94 121.25  11.25 139.87  7.68
Spleen weight (mg) WT 54.58  2.63 61.85  2.87 89.29  6.61
KO 75.84  4.81 87.54  4.24 123.67  7.34
Data represents mean  SE of three independent experiments. P value is P  0.005 for all except asterisk, P  0.02.
aBasal, n  7; RM-1 (3 d), n  11.
bBasal, n  10; RM-1 (3 d), n  16.
cTotal NK  percent NK cells  total cells (106).
dBasal, n  4; RM-1 (3 d), n  12.
eTotal CD3 cells  percent CD3 cells  total cells (106).
fTotal cells, n  6; spleen weight, n  12.
gTotal cells, n  4; spleen weight, n  14.
hTotal cells, n  10; spleen weight, n  10.
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1099 Esplugues et al.
B220, CD3, and DX5 spleen lymphocytes in CD69/
and WT mice (unpublished data). Further analyses using a
set of antibodies against different TCR Vs demonstrated
that the T cell expansion was polyclonal (unpublished data).
Finally, a moderate but significant increase in spleen size was
observed in unchallenged CD69/ mice (Table I B). To-
gether, these data suggest a role for CD69 as a regulator of
lymphocyte accumulation at inflammation sites. This altered
homeostasis might occur by modifications of lymphocytes
or their microenvironmental milieu.
Normal Trafficking of CD69/ Lymphocytes. The in-
creased number of lymphocytes in some activated tissues of
CD69/ mice might be due to altered trafficking of ac-
tivated lymphocytes in the absence of this molecule. To
determine a possible role of CD69 in lymphocyte traffick-
ing, we compared the migration of activated CD4 T lym-
phocytes from WT mice, expressing high levels of CD69
(unpublished data) and from CD69/ mice by in vivo
cell transfer. Purified CD4 T cells from CD69/ and
WT mice were PMA-activated for 3 h, introduced into
WT recipients, and their distribution was assayed 1 h later
(Fig. 5 A). No significant differences in the migration pat-
tern to various organs were observed for both CD69/
and WT CD4 T lymphocytes (Fig. 5 A). Almost identical
numbers of WT and CD69/ CD4 T lymphocytes
were also detected in all organs when 24-h migration ex-
periments were performed (Fig. 5 B). Likewise, homing
was identical for activated splenic B cells of CD69/ and
WT mice (unpublished data).
Augmented Lymphocyte Survival in CD69/ Mice. In
the periphery, homeostatic mechanisms regulate the expan-
sion and elimination of activated cells (25). To investigate
the mechanism of lymphocyte accumulation in CD69/
mouse spleen and peritoneum, we analyzed immune cell
survival in these mice. When peritoneal cell viability was
studied in vitro, an increase in cell survival was detected in
CD69/ compared with WT mice (Fig. 6 A). A signifi-
cant decrease in spontaneous apoptosis (24 h) of spleen lym-
phocytes from RM-1–challenged CD69/ (23.36 
1.73%, n  9) compared with WT mice (28.89  1.18%,
n  9) was detected as reduced DNA content by cell cycle
analyses (unpublished data; P  0.02). In addition, a signifi-
cant decrease in spontaneous apoptosis (48 h) of spleen lym-
phocytes from RM-1–challenged CD69/ (25.46 
0.5%, n  6) compared with WT mice (44.56  1.3%, n 
6) was also measured by caspase-3 activation analysis (Fig. 6
B; P  0.0001). Likewise, a significant decrease in sponta-
neous apoptosis (48 h) was observed when caspase-3 activa-
tion analyses were performed in DX5 CD3 NK spleno-
cytes from RM-1–challenged CD69/ (36.98  1.5%,
n  4) compared with WT mice (49.78  3.9%, n  4;
Fig. 6 C, P  0.02). Thus, it appears that differences in lym-
phocyte survival may contribute to the elevated spleen size
and cellularity observed in peritoneum of CD69/ mice.
Decreased TGF- and Increased Proinflammatory Factors in
CD69/ Mice. The anti–tumor response is orches-
trated by a wide array of growth factors and cytokines, and
altered expression of these factors may have a major impact
on immune responses. Therefore, we analyzed whether
the enhanced anti–tumor response of CD69/ as com-
pared with WT mice is influenced by differences in
chemokine and cytokine profiles. Assessment of relative
levels of cytokine mRNA was performed by RPA. Analy-
sis of peritoneal cells of RM-1–primed CD69/ mice
showed an increase in MCP-1 (133%), but the chemokines
MIP-1, MIP-1, IP-10, and eotaxin were unaltered (Fig.
7 A). To further examine MCP-1 production, we tested
the ability of LPS-activated peritoneal cells from thiogly-
collate-treated mice to produce MCP-1; the levels of
MCP-1 produced by peritoneal cells from CD69/
mice were almost three times higher than those of WT
mice (Fig. 7 B). In addition, analysis of peritoneal cell
RNA of RM-1–challenged CD69/ showed a change in
TGF- production compared with WT mice. CD69/
peritoneal cells produced less TGF-1, -2, and -3
transcripts than WT peritoneal cells (Fig. 7 A). The de-
crease in mRNA levels observed in four separate experi-
ments ranged from 33  5% for TGF-1 levels to 74 
19% for TGF-3. The decrease in TGF-2 RNA was sex-
Figure 5. Similar trafficking of activated CD69/ and WT CD4 T
cells. Short-term (A) and 24-h (B) trafficking patterns of activated
CD69/ and WT CD4 T cells do not differ. Distribution of radioac-
tivity in various organs at 1 or 24 h, respectively, after intravenous injec-
tion of activated 51Cr-labeled CD4 T cells. Note the numerical scales for
organs shown on the right. Four animals were used per experimental
group (bars  SD).
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1100 Role of CD69 in Tumor Immunity
dependent, varying from 20% for males to 110% for fe-
males. Analysis of splenocytes revealed only slight decreases
in TGF-1 and TGF-3 in CD69/ mice (unpub-
lished data). Analysis of peritoneal cells of RM-1–primed
CD69/ mice revealed an increase in cytokines IL-
12p35 (32–68%), IL-1 (27–64%), IL-1 (32% for males,
294% for females) compared with WT mice (Fig. 7 A). No
significant changes in LT-, IFN, MIF, IL-1–R, IL-18,
eotaxin, MIP-1, MIP-1, and IP-10 were found (Fig. 7
A and not depicted). Thus, these results suggest that the
immune cells from CD69/ mice have abnormal
chemokine and cytokine expression patterns, with defec-
tive synthesis of immunosuppressive factors and increased
production of proinflammatory cytokines.
Because innate immunity is highly involved in the in-
creased anti–tumor response observed in CD69/ mice,
we next determined cytokine mRNA levels in purified
NK cells and macrophages from RM-1–challenged
CD69/ and WT mice with quantitative real time RT-
PCR. These analyses showed a reduction in TGF-1 and
an increase in IL-1 and MCP-1 mRNA levels in both
macrophages and NK cells from CD69/ mice (Fig. 7
C). Therefore, NK cells and macrophages contribute to the
observed differences in TGF-, IL-1, and MCP-1 levels
between WT and CD69/ mice. These results are in ac-
cordance with the proposed role of TGF-1 as a repressor
in anti–tumor response (26, 27). These changes in chemo-
kines and cytokines observed in CD69/ mice may ac-
count for the more potent immune response and the en-
richment in T and NK lymphocytes observed in CD69/
as compared with WT mice.
Effect of TGF- Blockade in Anti–tumor response in WT
Mice. To establish a functional correlation between the
reduction in TGF- levels and the increased anti–tumor
response observed in CD69/ mice, WT mice were
treated with a blocking anti–TGF- mAb. TGF- block-
ade with the mAb prevented tumor development com-
pared with the control antibody or carrier (Fig. 8). These
results indicate that TGF- blockade in tumor-challenged
mice results in a similar phenotype to that seen in CD69-
deficient mice, thus underscoring the diminished produc-
tion of TGF- found in CD69/ mice as the basis for
their enhanced anti-tumor immunity.
CD69 Up-regulates TGF- Secretion. Based on the evi-
dence from CD69/ mice, CD69 may negatively regu-
late cell activation through TGF-. Thus, we examined
whether TGF- is regulated by signaling through CD69 in
T and NK cells. CD69 cross-linking induced TGF- pro-
duction in purified NK cells (Fig. 9 A), most of them
CD69 (unpublished data). Cross-linked, but not soluble,
anti-CD69 (mAb CD69.2.2) induced TGF-1 synthesis
independently of further costimulus (Fig. 9 A and not de-
picted). In these assays, increased active TGF-1 correlated
with total TGF-1 synthesis. Next, we analyzed TGF-1
production in activated T cells. Stimulation with anti-CD3
induced increased CD69 expression by purified spleen T
cells of B6 mice (Fig. 9 B). CD69 cross-linking on CD3-
activated T cells markedly induced TGF- production
(Fig. 9 C). This effect was not observed using a control iso-
type-matched antibody (Fig. 9 C), indicating that antibody
cross-linking of CD3 alone did not induce TGF- secre-
tion as described previously (28). Quantification of viable
and nonviable cells (Fig. 9 C) at 48 h after cell culture
showed a reduction in lymphocyte survival, which corre-
lates with enhanced TGF- levels. Together these results
establish a direct link between CD69 engagement and
TGF-1 synthesis in both NK and T cells, and may ac-
Figure 6. Attenuation of spontaneous cell death of CD69/ lym-
phocytes. (A) Unfractionated peritoneal cells of untreated mice were
seeded in culture medium and cell survival was measured by PI staining.
Values show the percentage of PI cells (mean  SD; n  3 for each
group). Results are representative of three independent experiments. (B)
Analysis of intracellular caspase-3 activity of spleen cells from WT (left)
and CD69/ (right) challenge mice (3 d with 105 RM-1). Caspase-3
activation was detected with fluorogenic substrate PhiPhiLux-G1D2.
PhiPhiLux staining on FL-1 versus forward scatter channels was dis-
played. (C) After gating on DX5 cells from spleen, caspase-3 activity was
assayed. At least 100,000 events were collected per sample. Experiments
were done twice with four and six mice per group; and similar results
were obtained.
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count for the increased TGF- production observed in
WT compared with CD69/ mice.
mAb-induced CD69 Down-regulation Enhances Anti–tumor
Responses. As an alternative approach, we assessed the ca-
pacity of the anti-CD69 mAb (CD69.2.2, mouse IgG1) to
modulate anti–tumor responses by blocking CD69 expres-
sion in vivo. As aforementioned, and in contrast to cross-
linked antibodies, soluble CD69.2.2 mAb did not induce
cytokine synthesis by CD69 cells (unpublished data).
Therefore, we quantified binding of labeled anti–mouse
IgG via FACS® analysis to determine if soluble mAb-2.2
could down-regulate CD69 expression.
A single injection of purified mAb-CD69.2.2 (500 g i.p.
per mouse) completely abolished CD69 expression in both
mature and immature hematopoietic cells in central and pe-
ripheral lymphoid organs (Fig. 10 A and not depicted), an
effect that lasted for more than 15 d. The blockade was spe-
cific in that no concomitant changes were detected in the
number of cells in lymphoid organs, or in the expression
levels of CD3, CD2, CD4, CD8 (Fig. 10 A), IgM, IgD,
Ly6G, B220, and CD5 surface molecules (unpublished data).
Moreover, mAb-CD69.2.2 did not mediate cell lysis by
complement activation and ADCC when tested in vitro
(unpublished data). Thus, mAb-CD69.2.2 elicited a remark-
ably specific down-regulation of CD69 expression in mu-
rine cells in vivo while operating as a nondepleting antibody.
To determine whether the mAb-CD69.2.2–induced
down-regulation of CD69 expression enhanced the anti–
Figure 7. Altered chemokine and cytokine pattern expression in
CD69/ mice. (A) Relative levels of cytokine and chemokine mRNA
in peritoneal cells from CD69/ () and WT () mice were analyzed
3 d after intraperitoneally inoculation of 105 RM-1 cells. Results are ex-
pressed in arbitrary densitometric units normalized for the expression of
GAPDH or L32 in each sample. Five animals were used per experimental
group, and results are representative of four independent experiments. (B)
MCP-1 levels in LPS-activated peritoneal cells from thioglycollated-
treated CD69/ and WT mice. Data represent the mean  SE (n  4
for each group) of one experiment representative of three independent
experiments. *, P  0.004. (C) Quantitative real-time RT-PCR analysis
of mRNA from CD69/ and WT purified peritoneal macrophages
(left) and NK cells (right) obtained from mice after 6 d of 105 i.p. RM-1
challenge. Three animals were used per experimental group, and results
are representative of one experiment.
Figure 8. Enhanced anti-tumor activity by blocking anti–TGF- in
WT mice. Survival plot of WT and CD69/ mice intraperitoneally in-
jected on day 0 with 104 RMA-S cells and treated with either 1D11 anti–
TGF- mAb (500 g/injection) or PBS on days 3 and 1 (before tu-
mor challenge), and at day 1 and every week after tumor inoculation. (n 
4). Results shown are representative of two independent experiments.
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tumor response, tumor progression was analyzed in mAb-
CD69.2.2 and isotype-control treated WT mice after in-
jections with RMA-S cells (106 i.p.). Tumor cell growth
was almost completely inhibited in animals treated with
mAb-CD69.2.2, whereas control mice presented signifi-
cant tumor cell overgrowth by 3 d (Fig. 10 B). (In addi-
tion, the number of pulmonary metastases was drastically
reduced in mAb-CD69.2.2–treated WT mice when com-
pared with isotype-treated controls after challenge with
RM-1 cells [104 i.v.; Fig. 10 C].) Treatment with anti-
CD69 antibodies inhibited (both) RMA-S overgrowth
(and RM-1–induced pulmonary metastases), thus support-
ing our working hypothesis that CD69 blockade enhances
anti–tumor responses.
Discussion
We found that CD69-deficient mice exhibit a potent
immune response against tumor cells, and that this phe-
nomenon is related to an altered balance in cellular and
soluble effector components. These findings support a
novel role for CD69 as a negative regulator of the immune
response. Previous in vitro studies proposed that CD69
acts as a stimulatory receptor for NK cells that can be
blocked by CD94 (15, 29). Earlier in vitro studies sug-
gested that CD69 is a proactivatory molecule in all leuko-
cytes, including NK cells (3, 11). Our findings here none-
theless indicate that CD69 exerts a down-regulatory role
in vivo in the immune system.
Figure 9. CD69 engagement
induces TGF-1 secretion in
NK and CD3 T lymphocytes.
Antibody engagement of CD69
induces TGF-1 secretion in
mouse-purified NK and T lym-
phocytes. Anti-CD69 (CD69.2.2)
or the isotypic control (murine
IgG1) was added followed by
cross-linking with goat anti–
mouse IgG antibody. (A) Active
(left) and total (right) TGF-1
were determined in NK cells af-
ter 24 h in culture supernatants.
(B) Purified resting CD3 T cells
were added to 96-well plates
coated with anti-CD3. Expres-
sion of CD69 after activation
with anti-CD3 were analyzed by
staining with FITC–anti-murine
CD69 mAb (shaded line) after
24 h of culture. Dotted line rep-
resents negative control. (C) An-
tibody engagement of CD69
induces TGF-1 secretion in
mouse T lymphocytes. Cells
were incubated in serum-free
medium for 72 h and TGF-1
was determined by ELISA. Data
are expressed as mean  SD of
replicate wells and are representative of three independent experiments.
(D) Cultured cells were removed and trypan blue was added. Dead cells
(trypan blue positive) was determined after 48 h of culture. Data represent
means of triplicate wells (bars  SD).
Figure 10. Therapeutic anti-tumor activity of anti-CD69 mAbs. 8-wk-
old C57BL/6 mice were treated intraperitoneally with 500 µg anti-
CD69.2.2 or with the isotype control (mouse IgG1). (A) Thymocytes
were prepared from the treated mice, and were subjected to flow cyto-
metric analysis. Representative profiles of CD4/CD8, CD2/CD69 (10 d
after mAb injection), and CD3/CD69 (15 d after mAb injection) are
shown with the percentage of cells in each quadrant. (B) Peritoneal cells
of WT mice were examined at day 3 after intraperitoneal injection of 106
RMA-S tumor cells. Mice were treated with mAb 1 d before tumor in-
oculation. Cells collected from the peritoneal lavage were analyzed and
forward and scattered FACS® analysis is shown. Marked gates correspond
to RMA-S tumor cells. (C) Mice were injected intravenously with 104
RM-1 and were treated with mAb on day 1 (before tumor challenge).
Number of lung metastases was counted 14 d after tumor inoculation. (C)
Open bar, control mice; closed bar, anti-CD69 mAb treated WT mice
(bars  SD). Results are representative of two independent experiments
(n  3).
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Studies of mice deficient in any of several molecules (IL-2,
IL-2R, CD45, CTLA-4, or TGF-) have shown that the
uncontrolled size and content of the immune compartment
causes enhanced immune reactivity (30–34). In these stud-
ies, the roles of T cells and T cell–derived cytokines have
been examined exhaustively, but the role of NK cells has
not. Our data show that an increase in the size of the NK
and T lymphocyte compartments enhances immune reac-
tivity toward tumor cells. This finding is consistent with a
unique functional role for NK cells’ and T lymphocytes’
interaction in the immune response as the primary source
of immunoregulatory cytokines (35, 36).
The tumoricidal activity of lymphocytes is dependent on
their activation state, the effector: target cell ratio, and the
susceptibility of the tumor targets. Our data show that the
immune response and survival to challenge with MHC
class I–deficient tumor cells (RMA-S and RM-1) is dra-
matically increased in CD69/ mice, and that this phe-
nomenon is not comparably observed when the same tu-
mor cells expressing MHC class I molecules (RMA) are
used. In the MHC class I–deficient tumor models used,
CD3 NK cells were the primary effector cells (22, 23), as
demonstrated by in vivo NK cell depletion experiments
and the increased anti–tumor response of CD69/
RAG-deficient mice. This concurs with the finding of en-
hanced NK cytotoxic activity in unfractionated peritoneal
cells from CD69/ mice. However, no differences in
the cytotoxic activity of purified splenic DX5 NK cells or
lymphokine-activated killer cells were detected between
WT and CD69/ mice.
Increased NK cell number at the site of tumor inocula-
tion seems to account for the increased NK cytotoxic ac-
tivity. An increased NK cell population showing normal
cytotoxic activity was reported in CD45/ mice (34).
In addition, increased T lymphocyte representation in
peritoneal cells of CD69/ mice, as well as T cell deple-
tion experiments, suggest that these cells are also involved
in tumor growth control, although to a lesser extent than
NK cells. Although the results in RAG-2/ mice
showed T lymphocytes are not required for the increased
anti–tumor response observed in this in vivo experimental
system, these data are not directly comparable to those ob-
tained in RAG-2/ mice because lymphocyte-deficient
mice have major differences in cell homeostasis as com-
pared with normal control mice. Our data are thus com-
patible with both NK and T lymphocytes participating in
the augmented tumor growth control in CD69/ mice.
It is feasible that T cell–derived cytokines contribute to the
increased NK anti–tumor response seen in CD69/
mice, as the tumor cells studied are not sensitive to lysis by
CTLs. Multiple interactions between NK and T cells have
been reported. In this regard, the critical role of CD4 T
cells in the rejection of MHC class I tumors has been
demonstrated previously (37). Likewise, it has been shown
that NK and CD8 T cells interaction results in TGF-
generation (36).
After activation, lymphocytes display profound alter-
ations in their in vivo homing behavior (38). Because
CD69 becomes up-regulated on T cells with a similar ki-
netics as traffic changes occur, it seemed reasonable that
CD69 may have a role in retargeting lymphocytes to other
compartments upon activation. Comparison of CD69/
and WT lymphocytes nonetheless showed no significant
differences in the trafficking to various body sites. Thus, it
is unlikely that the accumulation of lymphocytes observed
in spleen and peritoneum of CD69/ mice is due to de-
fects in trafficking to competing organs. Alternatively, the
changes in cellularity at these sites in untreated CD69/
mice, and especially in CD69/ mice inoculated with
tumor cells, might be caused by an altered host lymphocyte
turnover. Therefore, we tested whether the increased cell
numbers in CD69/ mice might be due to alterations in
the fate of cells. Peritoneal cell and splenocyte survival was
increased in CD69/ compared with WT mice, and cell
cycle and caspase-3 activity analysis revealed reduced apop-
tosis in CD69/ cells. Several in vitro inducers of differ-
ent apoptotic routes in lymphocytes had similar effects
when WT and CD69/ mice were compared (unpub-
lished data). We previously used a specific peptide to in-
duce proliferation in a TCR transgenic model (4) and
showed that lymphocyte proliferation was not altered in
CD69-deficient mice. Therefore, the finding of diminished
lymphocyte death, coupled with the fact that a high pro-
portion of activated lymphocytes migrating through the
body normally die within 24 h (70%; reference 39) may
account, at least in part, for the increased lymphocyte pop-
ulation found in activated locations in CD69/ mice.
The anti-tumor immune response is associated with in-
creased spleen size. In this regard, an enlargement of spleen
size, more accentuated in tumor-challenged mice, has been
observed in CD69/ as compared with WT mice. Nev-
ertheless, as reported previously (4), similar splenic cell sub-
sets were detected in CD69/ and WT mice. However,
this analysis did not include a careful examination of sub-
populations such as the late immune response subpopula-
tion described recently (40). Our work on the distribution
of activated lymphocytes in CD69/ mice agrees with
that of others, in that reduced cell death accounts for pref-
erential tissue distribution of activated T cells (41).
Chemokines orchestrate the migration of immune cells
at different stages of maturation and activation. Several pa-
pers have suggested that the innate response to tumors is
regulated by a cytokine/chemokine network produced by
interaction of antigen-presenting cells, NK cells, and stro-
mal elements. In this regard, various chemokines are
known to have anti-tumor activity(16), and enhancing ac-
tivity of lymphocytes by MCP-1 on cytotoxicity, migra-
tion, and tumor suppression has been reported (42, 43).
Our results show that MCP-1 production of in vitro–acti-
vated peritoneal cells and MCP-1 mRNA levels in the
tumor challenged peritoneal cavity from CD69/ mice
are increased compared with WT mice, possibly explaining
the increased influx of immune cells and antitumor activity
in these animals.
The TGF- family of cytokines is involved in cell
growth regulation and apoptosis (44). Lymphoid cells pro-
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duce TGF-, and the critical anti-inflammatory role of this
cytokine has been demonstrated in mice lacking TGF-1
and TGF- signaling in T cells, which develop inflamma-
tory and autoimmune disorders, respectively (45). TGF-
has an important immunosuppressive role in that it inhibits
anti-tumor immune response. Recently, it has been re-
ported that blockade of TGF- signaling in T cells en-
hances anti-tumor immunity by facilitating an expansion of
tumor-specific CD8 T cells (27). The analysis of cells in-
volved in tumor rejection in CD69/ mice showed a
decrease in TGF- mRNA synthesis, which appears to be
associated with an increased production of MCP-1 and
proinflammatory cytokines such as IL-1, IL-1, and IL-
12. Moreover, in vivo blockade of TGF- in WT mice
caused an increase in anti–tumor responses comparable to
that detected in CD69/ mice, indicating that the di-
minished production of TGF- found in CD69/ mice
is a key factor for their enhanced anti-tumor immunity.
Thus, and although it is possible that CD69 might signal
TGF- and proinflammatory cytokines independently, the
increase in proinflammatory cytokines in CD69/ mice
might be subsequent to the decrease in TGF- secretion as
TGF- inhibits proinflammatory cytokine secretion.
It is well-known that TGF- inhibits T cell prolifera-
tion, differentiation, and CTL responses (46, 47). On the
other hand, MCP-1 enhances lymphocyte migration and
cytotoxicity (43, 48). The combination of increased syn-
thesis of MCP-1 and proinflammatory cytokines and de-
creased TGF- production may lead to enhanced T and
NK cell responses, accounting for the increased tumor sur-
veillance in CD69/ mice. Further work is necessary to
investigate the role of CD69 in cytokine and chemokine
production in different cell subsets.
Our data on cytokine synthesis suggested that CD69-
mediated signaling was linked to TGF- gene expression,
and this linkage was confirmed by CD69 cross-linking. Be-
cause CD69 engagement induces substantial levels of TGF-,
and this cytokine is a potent inhibitor of lymphocyte-
mediated responses, this finding has implications for our
understanding of in vivo CD69 function. It is reasonable to
envision that TGF- may play a role in suppression of lym-
phocyte activation initiated by CD69 interaction, and that
elimination of CD69 results in a partial reduction in TGF-
and augmented production of proinflammatory cytokines
and chemokines, which may account for the enhanced
anti-tumor immune response observed in CD69/
mice. The increased survival of splenocytes and peritoneal
immune cells in CD69/ mice may be related to defec-
tive TGF- production, and therefore to a diminution in
proapoptotic TGF- stimuli (44). Conversely, increased
TGF- production may be consequence to increased cell
apoptosis due to TGF- released by dying cells (49). Alter-
natively, the changes in TGF- secretion and apoptotic
processes might be independently induced through CD69
signaling. Consistent with this, TGF- secretion was not
detected in nonactivated cell culture supernatants, although
differences in spontaneous apoptosis were observed (un-
published data). In addition, our previous observations of
an alteration in the pre–B cell stage of B cell development
and an enhancement of T cell–dependent IgG isotype-spe-
cific responses in CD69/ mice (4) are in agreement
with the role of TGF- in B cell differentiation and immu-
noglobulin production (19). Nevertheless, study of TGF-
production during B cell ontogeny and antigen-dependent
immune responses in T cells has not yet been performed in
CD69/ mice. Thus, CD69 expression and interaction
with its putative ligand may contribute to negative regula-
tion of the immune response, and to suppression of the in-
flammatory response. This work significantly contributes to
understand the role of CD69 in vivo, revealing its function
as an immunomodulatory molecule through the produc-
tion of TGF-. In this regard, anti-CD69 antibody treat-
ment in WT mice induced a deficiency in CD69 expres-
sion that resulted in augmented anti–tumor response,
further supporting evidence that a physiological function of
CD69 as a anti-tumor repressor. These results showed the
possibility of a novel approach for the therapy of tumors
and other immune-mediated diseases by targeting CD69.
We are currently studying the mechanisms of action of
anti-CD69 mAbs treatment in the control of metastasis and
tumor growth. Future work is needed to define the molec-
ular basis of anti-CD69 tumor therapy.
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